Exercise and protein intake can preserve—even increase—lean mass during GLP-1 drug treatment
Three case studies show that combining semaglutide/tirzepatide with resistance training 3-5x/week and protein intake of 0.7-1.7 g/kg enabled lean tissue preservation (1 patient: -6.9% lean) or even gain (2 patients: +2.5%, +5.8%) despite 13-33% total weight loss.
Quick Facts
What This Study Found
Case 1: -33% weight, -53.4% fat, -6.9% lean (8.7% of loss as lean). Case 2: -26.8% weight, -61.6% fat, +2.5% lean. Case 3: -13.2% weight, -46.9% fat, +5.8% lean. Exercise: 4-7d/week, RT 3-5d/week. Protein: 0.7-1.7 g/kg BW (1.6-2.3 g/kg FFM).
Key Numbers
How They Did This
Case series. 3 patients (2F, 1M; BMI 32.9-51.9). Semaglutide or tirzepatide. Body composition by DXA or BIA. Exercise and protein intake tracking.
Why This Research Matters
The muscle loss concern with GLP-1 drugs has been a major criticism. These cases demonstrate that with intentional exercise and protein, lean mass can be preserved or even gained—directly countering the "Ozempic muscle" concern.
The Bigger Picture
This provides the strongest individual-level evidence that GLP-1 drug-related muscle loss is preventable with lifestyle intervention. It shifts the narrative from "GLP-1 drugs cause muscle loss" to "unsupported GLP-1 therapy causes muscle loss."
What This Study Doesn't Tell Us
Only 3 patients. Self-selected motivated individuals. No control comparison. Different GLP-1 drugs and doses. Short case series.
Questions This Raises
- ?What minimum exercise dose preserves lean mass on GLP-1 drugs?
- ?Is resistance training or protein intake more important?
- ?Would these results replicate in less motivated patients?
Trust & Context
- Key Stat:
- Lean mass gained, not lost 2 of 3 GLP-1 drug patients GAINED lean tissue during 13-27% weight loss by combining resistance training and adequate protein—disproving the inevitability of muscle loss
- Evidence Grade:
- Case series—lowest evidence but powerful individual demonstrations.
- Study Age:
- Published in 2025.
- Original Title:
- Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.
- Published In:
- SAGE open medical case reports, 13, 2050313X251388724 (2025)
- Authors:
- Tinsley, Grant M, Nadolsky, Spencer
- Database ID:
- RPEP-13812
Evidence Hierarchy
Frequently Asked Questions
Will I lose muscle on semaglutide?
Not necessarily. These three cases show that with resistance training (3-5 times per week) and adequate protein intake, you can preserve or even gain lean tissue while losing substantial weight. Two patients actually gained lean mass while losing 13-27% of their body weight—with 47-62% of weight lost being fat.
What should I do to protect my muscles on GLP-1 drugs?
Based on these cases: (1) Do resistance/strength training at least 3 times per week, (2) eat adequate protein (at least 0.7 g per kg of body weight, ideally more), and (3) maintain regular physical activity 4-7 days per week. The patients who did this lost weight predominantly from fat while preserving or building muscle.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13812APA
Tinsley, Grant M; Nadolsky, Spencer. (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.. SAGE open medical case reports, 13, 2050313X251388724. https://doi.org/10.1177/2050313X251388724
MLA
Tinsley, Grant M, et al. "Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.." SAGE open medical case reports, 2025. https://doi.org/10.1177/2050313X251388724
RethinkPeptides
RethinkPeptides Research Database. "Preservation of lean soft tissue during weight loss induced ..." RPEP-13812. Retrieved from https://rethinkpeptides.com/research/tinsley-2025-preservation-of-lean-soft
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.